A5005499715- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Cancer-related molecular mechanisms research
- Esophageal and GI Pathology
- MicroRNA in disease regulation
- RNA modifications and cancer
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Transplantation: Methods and Outcomes
- Cancer Genomics and Diagnostics
- Pleural and Pulmonary Diseases
- Circular RNAs in diseases
- Tracheal and airway disorders
- Cardiac, Anesthesia and Surgical Outcomes
- Surgical Simulation and Training
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- Cancer-related gene regulation
- Cancer Immunotherapy and Biomarkers
- Venous Thromboembolism Diagnosis and Management
- Pancreatic and Hepatic Oncology Research
- Medical Imaging and Pathology Studies
- Advanced Radiotherapy Techniques
- Anatomy and Medical Technology
- Gastroesophageal reflux and treatments
University of Michigan
2016-2025
Michigan Medicine
2011-2024
Memorial Sloan Kettering Cancer Center
2024
Faculty of 1000 (United States)
2023
RELX Group (United States)
2023
Thoracic Surgery Foundation
2012-2022
Society of Thoracic Surgeons
2015-2022
American Association for Thoracic Surgery
2022
Ann Arbor VA Medical Center
2013-2021
Takeda (Japan)
2021
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies metastatic NSCLC, because therapeutic recommendations are rapidly changing disease. For example, new were added atezolizumab, ceritinib, osimertinib, pembrolizumab 2017 updates.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management patients with NSCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. Patients metastatic lung cancer who are eligible targeted therapies or immunotherapies now surviving longer. This selection from the NSCLC focuses on actionable mutations.
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates in immunotherapy. For the 2020 update, systemic therapy regimens have been categorized using a new preference stratification system; certain are now recommended as "preferred interventions," whereas others either "other interventions" or "useful under circumstances."
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates to the regarding targeted therapies, immunotherapies, and their respective biomarkers.
These NCCN Guidelines Insights focus on recent updates to the 2015 for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it important test tumor tissue from determine whether they alterations that make them candidates therapies. describe different testing methods currently available determining 2 most commonly actionable alterations, notably anaplastic lymphoma kinase (ALK) gene...
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates to the targeted therapy and immunotherapy sections in Guidelines. For 2018 update, a new section biomarkers was added.
These NCCN Guidelines Insights focus on recent updates in the 2016 for Non–Small Cell Lung Cancer (NSCLC; Versions 1–4). will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, patients with metastatic NSCLC. For update, panel recommends immune checkpoint inhibitors preferred agents (in absence of contraindications) second-line beyond (subsequent) therapy NSCLC (both squamous nonsquamous histologies). Nivolumab pembrolizumab are based improved overall survival rates,...
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations management of disease in patients with NSCLC. These Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options eligible resectable
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance relapse, and subsequent treatment. panel has updated list recommended targeted therapies based on recent FDA approvals clinical data. This selection from NSCLC focuses advanced or metastatic actionable molecular biomarkers.
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) focuses on principles of radiation therapy (RT), which include following: (1) general early-stage, locally advanced, and advanced/metastatic NSCLC; (2) target volumes, prescription doses, normal tissue dose constraints advanced/palliative RT; (3) RT simulation, planning, delivery. Treatment recommendations should be made by a multidisciplinary team, including...
We describe a case of proven transmission SARS-CoV-2 from lung donor to recipient. The had no clinical history or findings suggestive infection with and tested negative by reverse transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal (NP) swab obtained within 48 h procurement. Lower respiratory tract testing was not performed. recipient developed fever, hypotension, pulmonary infiltrates posttransplant day (PTD) 3, RT-PCR for an NP specimen non-reactive, but positive...
// Zhuo Zhang 1 , Hiroe Shiratsuchi 2 Jules Lin 3 Guoan Chen Rishindra M. Reddy Ebrahim Azizi 2, 4 Shamileh Fouladdel Andrew C. Chang Hui Jiang 7 Meghna Waghray 3, 4, 5 Gary Luker 8 Diane Simeone Max S. Wicha David G. Beer Nithya Ramnath 6 Sunitha Nagrath 1, Department of Chemical Engineering, Biomedical University Michigan, Ann Arbor, MI 48109 Internal Medicine, Surgery, Translational Oncology Program, Molecular and Integrative Physiology, Veterans Administration Arbor Healthcare System,...
Early detection of metastasis can be aided by circulating tumor cells (CTC), which also show potential to predict early relapse. Because the limited CTC numbers in peripheral blood stages, we investigated CTCs pulmonary vein accessed during surgical resection tumors. Pulmonary (PV) and (Pe) specimens from patients with lung cancer were drawn perioperative period assessed for burden using a microfluidic device. From 108 samples analyzed 36 patients, PV had significantly higher number compared...
Abstract The long noncoding RNA (lncRNA) MIR22HG has previously been identified as a prognostic marker in hepatocellular carcinoma. Here, we performed comprehensive analysis of lncRNA expression profiles from RNA-Seq data and report that plays similar role lung cancer. Analysis 918 cancer normal tissues cell lines revealed was significantly downregulated cancer; this decreased associated with poor patient survival. bound stabilized the YBX1 protein. Silencing triggered both survival death...
Abstract The aim of this study was to identify differentially-expressed miRNAs in the serum non-small cell lung cancer (NSCLC) patients that might be a clinically-useful tool for early detection. We performed miRNA expression profile analysis using TaqMan OpenArray Human panel discovery set 70 samples obtained at tumor resection and 22 non-cancer subjects (NC). Selected were then validated by quantitative PCR an independent validation from LC (n = 84) NC 23). Sixty significantly up-regulated...
Preoperative risk assessment, particularly for patient frailty, remains largely subjective. This study evaluated the relationship between core muscle size and outcomes following esophagectomy malignancy. Using preoperative computed tomography scans in 230 subjects who had undergone transhiatal cancer 2001 2010, lean psoas area (LPA), measured at fourth lumbar vertebra, was determined. Cox proportional hazards regression employed to analyze overall survival (OS) disease-free (DFS) adjusted...
These NCCN Guidelines Insights focus on recent updates to the for Malignant Pleural Mesothelioma (MPM). discuss systemic therapy regimens and surgical controversies MPM. The panel recommends cisplatin/pemetrexed (category 1) patients with also now bevacizumab/cisplatin/pemetrexed as a first-line option unresectable MPM who are candidates bevacizumab. complete version of MPM, available at NCCN.org, addresses all aspects management including diagnosis, evaluation, staging, treatment,...